Press-release for stocks related to vaccine for vxrt

Prices are updated after-hours

tags : Vaccine symbols : Vxrt

save search

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -25.48% | O: 0.0% H: 7.38% C: 5.74%
vaccine congress world

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -24.24% | O: 0.83% H: 4.13% C: -3.72%
primate vaccine sars-cov-2 publication preclinical

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Published: 2024-01-19 (Crawled : 13:30) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| 14.38% | O: 2.1% H: 1.04% C: -8.52%
covid-19 award candidate vaccine million nextgen study

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| 50.76% | O: 1.16% H: 1.64% C: -1.64%
candidate vaccine norovirus trial

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| 40.79% | O: -2.03% H: 7.48% C: 5.3%
candidate vaccine norovirus trial

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| 27.04% | O: 0.11% H: 0.49% C: -2.58%
europe vaccine congress world

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
Published: 2023-09-06 (Crawled : 20:00) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| 13.64% | O: -1.25% H: 1.27% C: -6.84%
candidate vaccine norovirus topline study phase 2

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
Published: 2023-07-06 (Crawled : 12:00) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| 25.17% | O: 0.51% H: 4.11% C: -1.27%
candidate vaccine norovirus positive topline study phase 2

Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
Published: 2023-03-29 (Crawled : 13:20) - biospace.com/
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| 21.18% | O: 3.97% H: 3.85% C: 2.63%
vaccine

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -22.96% | O: 1.69% H: 0.0% C: -2.5%
candidate vaccine norovirus funding study

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
Published: 2022-11-22 (Crawled : 15:20) - biospace.com/
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -32.16% | O: 0.0% H: 1.49% C: 1.49%
immunotherapy vaccine

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
Published: 2022-10-10 (Crawled : 14:00) - biospace.com/
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -52.9% | O: -0.52% H: 0.23% C: -5.21%
europe vaccine

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
Published: 2022-09-01 (Crawled : 11:00) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -70.67% | O: -2.26% H: 4.62% C: 3.96%
covid-19 candidate vaccine positive study

Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
Published: 2022-07-20 (Crawled : 13:00) - biospace.com/
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -77.04% | O: 2.53% H: 8.13% C: 4.93%
covid-19 candidate vaccine

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
Published: 2022-07-14 (Crawled : 12:20) - globenewswire.com
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -79.39% | O: -0.91% H: 1.14% C: -3.66%
covid-19 preclinical vaccine program

New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
Published: 2022-06-03 (Crawled : 15:20) - biospace.com/
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -74.25% | O: -0.85% H: 5.57% C: 4.29%
covid-19 preclinical vaccine pre-clinical

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
Published: 2022-06-02 (Crawled : 16:00) - biospace.com/
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -73.65% | O: -1.16% H: 5.28% C: 3.52%
vaccine trial norovirus positive phase 2b

Vaxart to Present at World Vaccine Congress Washington 2022 on April 20
Published: 2022-04-14 (Crawled : 13:00) - biospace.com/
VXRT | $0.9091 -0.11% -1.38% 1.6M

Health Technology

| -81.37% | O: -1.02% H: 0.93% C: -3.52%
vaccine